2024 and ACE Inhibitor - Cardiovascular Update

ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy

DAIC

APRIL 9, 2024

The PROACT study reported no impact on cardiotoxicity biomarkers or secondary endpoints related to heart function among patients who took high doses of enalapril, an ACE inhibitor, along with high doses of anthracyclines. The mean dose of enalapril among those who were randomized to take the ACE inhibitor was 17.7mg.

ACE Inhibitor

ACE Inhibitor Cancer Biomarkers Heart Failure

What Should Your Blood Pressure Be?

Dr. Paddy Barrett

NOVEMBER 29, 2024

Most people with high blood pressure will be treated with an ACE inhibitor, ARB, calcium channel blocker or a diuretic. 2024 Nov;81(11):2329-2339. 6 Mortality and Morbidity Among Individuals With Hypertension Receiving a Diuretic, ACE Inhibitor, or Calcium Channel Blocker: A Secondary Analysis of a Randomized Clinical Trial.

Blood Pressure

Blood Pressure ACE Inhibitor Hypertension Cardiovascular Disease

FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure

DAIC

MARCH 26, 2025

In fact, a 2024 report on heart failure trends and outcomes published in the Journal of Cardiac Failure showed that in patients with heart failure with preserved ejection fraction, 5-year mortality was 75.7%. Detailed results were presented at ESC Congress 2024 and simultaneously published in the New England Journal of Medicine.

Heart Failure

Heart Failure Preserved Ejection Fraction Kidney Disease ACE Inhibitor

Webinars

Bridging Innovation & Patient Care: The Growing Role of AI

MORE WEBINARS

Digital Consults to Enhance Heart Failure Treatment: The ADMINISTER Trial

Cardiology Update

AUGUST 4, 2024

This includes beta-blockers, ACE inhibitors, ARBs, ARNIs, MRAs, and SGLT2 inhibitors. ESC Heart Failure 2024; 11 : 560–569. The 2021 European Society of Cardiology guidelines recommend guideline-directed medical therapy (GDMT) for patients with HF with reduced ejection fraction (HFrEF). Original article: Man JP et al.

Heart Failure

Heart Failure ACE Inhibitor COVID-19 Quality of Life

ACE Inhibitor and Angiotensin Receptor Blocker use during Pregnancy: data from the ESC Registry Of Pregnancy And Cardiac disease (ROPAC)

The American Journal of Cardiology

AUGUST 8, 2024

Publication date: Available online 7 August 2024 Source: The American Journal of Cardiology Author(s): Johanna A. van der Zande, Karishma P. Ramlakhan, Katja Prokselj, Edison Muñoz-Ortiz, Amalia Baroutidou, Magdalena Lipczynska, Edit Nagy, Tobias Rutz, Arie Franx, Roger Hall, Mark R. Johnson, Jolien W. Roos-Hesselink, ROPAC investigators

ACE Inhibitor

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

APRIL 6, 2024

Butler will be available to the media in a press conference on Saturday, April 6, 2024, at 10:45 a.m. Butler will present the study, “Empagliflozin After Acute Myocardial Infarction: Results of the EMPACTMI Trial,” on Saturday, April 6, 2024, at 9:30 a.m. ET / 14:45 UTC in Room B203. ET / 13:30 UTC in the Hall B-1 Main Tent.

Heart Attack

Heart Attack Heart attacks Heart Failure Outpatient

Abstract TMP97: Temporal Trends in Black-White Differences of Antihypertensive Treatment in Individuals With and Without History of Stroke: Reasons for Geographic and Racial Differences in Stroke (REGARDS)

Stroke Journal

FEBRUARY 1, 2024

Stroke, Volume 55, Issue Suppl_1 , Page ATMP97-ATMP97, February 1, 2024. Introduction:In 2014, the Eighth Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC8) included race-specific recommendations for antihypertensive treatments (e.g. calcium channel blockers [CCBs] for Black persons).

ACE Inhibitor

ACE Inhibitor Stroke Strokes Blood Pressure

Abstract 4142012: Ectasias of Multiple Coronary Arteries and a Coronary Cameral Fistula Between Right Coronary Artery and Coronary Sinus

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4142012-A4142012, November 12, 2024. Cardiac MRI did not show significant ischemic findings.The patient received medical therapy consisting of antiplatelet agents, high dose statin, beta blocker and ACE inhibitor, as well as diuretics.

Coronary Artery Bypass Graft

Coronary Artery Bypass Graft ACE Inhibitor Coronary Angiogram Aneurysm

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

DAIC

APRIL 6, 2024

While composite of death and heart failure hospitalizations was not significantly reduced, empagliflozin may help reduce heart failure risks after a heart attack, according to results from the EMPACT-MI trial presented on day one of the American College of Cardiology Scientific Sessions, ACC.24, 24, being held in Atlanta, GA.

Heart Attack

Heart Attack Heart attacks Heart Failure Outcomes

Dishing out the meds

The British Journal of Cardiology

JANUARY 16, 2024

Twenty years ago, Wald and Law 1 hypothesised that, if a combination pill could be made including aspirin, folic acid, a statin, and a low-dose diuretic, beta blocker and angiotensin-converting enzyme (ACE) inhibitor (thus, allowing for the simultaneous modification of four different risk factors: low-density lipoprotein [LDL]-cholesterol, blood pressure, (..)

ACE Inhibitor

ACE Inhibitor Blood Pressure Risk Factors Cardiovascular Disease

Abstract 4134796: Safety of over 1000 consecutive, selected low risk patients with accelerated discharge from a chest pain unit with early generation cardiac troponin use, no cardiac functional or anatomic testing and no clinical risk scores

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4134796-A4134796, November 12, 2024. Women received more discharge cardiac medications than men: antiplatelet agents, statins, beta blockers, ACE inhibitors, angiotensin II blockers, calcium channel blockers, and nitrates (p=0.0002 - 0.04).Follow-up

Chest Pain

Chest Pain ACE Inhibitor Cardiac Function Coronary Artery Disease

Understanding the failings of yesterday to improve the outcomes of tomorrow: a CardioRenal story

The British Journal of Cardiology

JULY 17, 2024

“In spite of the accumulating evidence of their efficacy, established treatments for maintaining renal function remain woefully underutilized. Clinicians and health care systems must be encouraged to make use of these treatments.”

Kidney Disease

Kidney Disease Outcomes Diabetes Heart Failure

Abstract 4141312: Safe Initial Dosing of Innovative Enalapril Orodispersible Minitablets in Newly Treated Newborns, Infants and Young Children with Heart Failure – Results of a Population Pharmacokinetic Analysis of the LENA Trials

Circulation

NOVEMBER 11, 2024

Circulation, Volume 150, Issue Suppl_1 , Page A4141312-A4141312, November 12, 2024. Methods:We analyzed data of ACE inhibitor naïve subjects with heart failure due to congenital heart disease (n=31) or dilated cardiomyopathy (n=3) from the prospective, open-label, multicenter phase II/III pharmacokinetic bridging studies using NONMEM®.

Heart Failure

Heart Failure Innovation ACE Inhibitor Congenital Heart Disease

ACE Inhibitor Not Protective Against Heart Damage from Chemotherapy

What Should Your Blood Pressure Be?

FDA Accepts, Grants Priority Review Designation for Bayer's msNRA for Patients with Heart Failure

Webinars

Digital Consults to Enhance Heart Failure Treatment: The ADMINISTER Trial

ACE Inhibitor and Angiotensin Receptor Blocker use during Pregnancy: data from the ESC Registry Of Pregnancy And Cardiac disease (ROPAC)

SGLT-2 Inhibitors Show Mixed Results After Heart Attack

Abstract TMP97: Temporal Trends in Black-White Differences of Antihypertensive Treatment in Individuals With and Without History of Stroke: Reasons for Geographic and Racial Differences in Stroke (REGARDS)

Abstract 4142012: Ectasias of Multiple Coronary Arteries and a Coronary Cameral Fistula Between Right Coronary Artery and Coronary Sinus

EMPACT-MI Trial Outcomes Reported at ACC24: SGLT-2 Inhibitors Show Mixed Results After Heart Attack

Dishing out the meds

Abstract 4134796: Safety of over 1000 consecutive, selected low risk patients with accelerated discharge from a chest pain unit with early generation cardiac troponin use, no cardiac functional or anatomic testing and no clinical risk scores

Understanding the failings of yesterday to improve the outcomes of tomorrow: a CardioRenal story

Abstract 4141312: Safe Initial Dosing of Innovative Enalapril Orodispersible Minitablets in Newly Treated Newborns, Infants and Young Children with Heart Failure – Results of a Population Pharmacokinetic Analysis of the LENA Trials

Stay Connected